The EU Home Affairs Sub-Committee takes evidence from medical practitioners on the health implications of leaving Euratom. The evidence session covers the implications of leaving Euratom on the safe and timely transport and delivery of medical radioisotopes, and the options available for future relations with Euratom.
Wednesday 22 November, Committee Room 3, Palace of Westminster
- Professor Michael Rees, Co-Chair of the Medical Academic Staff Committee, BMA
- Dr John Buscombe, President-Elect, British Nuclear Medicine Society
- Dr Jeanette Dickson, Vice President, Faculty of Clinical Oncology, Royal College of Radiologists
- What medical products and procedures are likely to be impacted by the UK's departure from the Euratom treaty?
- What would you identify as the key safeguards in the Euratom Treaty for the safe and timely transport and delivery of medical radioisotopes? What safeguards will need to be maintained in the future?
- What are the implications for hospitals and other health providers and for patients of a disruption to the supply of radioisotopes?
- Do you foresee any opportunities arising from leaving Euratom for your members or for patients in the UK? Should the UK invest in alternative technologies to produce radioisotopes? What other steps could mitigate any negative consequences of leaving Euratom?